Akebia Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
AKBA$0.54+1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity (Deficit
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'Equity (Deficit) | |||||||
|---|---|---|---|---|---|---|---|
| (dollars in thousands) · Shares · Amount | |||||||
| Balance at December 31, 2022 | 184,135,714 | $2 | $1,562,247 | $6 | $(1,557,025) | $5,230 | |
| Proceeds from sale of stock under employee stock purchase plan | 103,500 | — | 34 | — | — | 34 | |
| Stock-based compensation expense | — | — | 2,489 | — | — | 2,489 | |
| Restricted stock unit vesting | 1,596,732 | — | — | — | — | — | |
| Net loss | — | — | — | — | (26,876) | (26,876) | |
| Balance at March 31, 2023 | 185,835,946 | $2 | $1,564,770 | $6 | $(1,583,901) | $(19,123) | |
| Stock-based compensation expense | — | — | 3,490 | — | — | 3,490 | |
| Restricted stock unit vesting | 2,292,923 | — | — | — | — | — | |
| Net income | — | — | — | — | (11,172) | (11,172) | |
| Balance at June 30, 2023 | 188,128,869 | $2 | $1,568,260 | $6 | $(1,595,073) | $(26,805) | |
| Proceeds from sale of stock under employee stock purchase plan | 96,694 | — | 50 | — | — | 50 | |
| Stock-based compensation expense | — | — | 1,824 | — | — | 1,824 | |
| Restricted stock unit vesting | 88,244 | — | — | — | — | — | |
| Net loss | — | — | — | — | (14,489) | (14,489) | |
| Balance at September 30, 2023 | 188,313,807 | $2 | $1,570,134 | $6 | $(1,609,562) | $(39,420) | |
| Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive Income · AccumulatedDeficit · Total Stockholders'Deficit | |||||||
| (dollars in thousands) | Shares | Amount | |||||
| Balance at December 31, 2023 | 194,582,539 | $2 | $1,578,358 | $6 | $(1,608,950) | $(30,584) | |
| Issuance of common stock, net of issuance costs | 13,261,311 | — | 18,740 | — | — | 18,740 | |
| Proceeds from sale of stock under employee stock purchase plan | 92,321 | — | 70 | — | — | 70 | |
| Exercise of options | 280,260 | — | 141 | — | — | 141 | |
| Stock-based compensation expense | — | — | 2,360 | — | — | 2,360 | |
| Restricted stock unit vesting | 1,237,718 | — | — | — | — | — | |
| Net loss | — | — | — | — | (17,985) | (17,985) | |
| Balance at March 31, 2024 | 209,454,149 | $2 | $1,599,669 | $6 | $(1,626,935) | $(27,258) | |
| Exercise of options | 23,892 | — | 14 | — | — | 14 | |
| Stock-based compensation expense | — | — | 2,072 | — | — | 2,072 | |
| Restricted stock unit vesting | 451,104 | — | — | — | — | — | |
| Net loss | — | — | — | — | (8,582) | (8,582) | |
| Balance at June 30, 2024 | 209,929,145 | $2 | $1,601,755 | $6 | $(1,635,517) | $(33,754) | |
| Issuance of common stock, net of issuance costs | 1,242,662 | — | 1,662 | — | — | 1,662 | |
| Proceeds from sale of stock under employee stock purchase plan | 97,411 | — | 83 | — | — | 83 | |
| Exercise of options | 2,312 | — | — | — | — | — | |
| Stock-based compensation expense | — | — | 1,646 | — | — | 1,646 | |
| Restricted stock unit vesting | 270,592 | — | — | — | — | — | |
| Net loss | — | — | — | — | (20,039) | (20,039) | |
| Balance at September 30, 2024 | 211,542,122 | $2 | $1,605,146 | $6 | $(1,655,556) | $(50,402) | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.